Circulating IL 6 and IL 23 Levels in Systemic Lupus Erythematosus Patients and Association with Disease Activity
Fathy, F., Thabet, R., Elgendy, A., abo el magd, N. (2023). Circulating IL 6 and IL 23 Levels in Systemic Lupus Erythematosus Patients and Association with Disease Activity. EKB Journal Management System, 32(1), 169-178. doi: 10.21608/ejmm.2023.277801
Fatma el zahraa Y. Fathy; Rasha N. Thabet; Aya Elgendy; Nagwa Mahmoud abo el magd. "Circulating IL 6 and IL 23 Levels in Systemic Lupus Erythematosus Patients and Association with Disease Activity". EKB Journal Management System, 32, 1, 2023, 169-178. doi: 10.21608/ejmm.2023.277801
Fathy, F., Thabet, R., Elgendy, A., abo el magd, N. (2023). 'Circulating IL 6 and IL 23 Levels in Systemic Lupus Erythematosus Patients and Association with Disease Activity', EKB Journal Management System, 32(1), pp. 169-178. doi: 10.21608/ejmm.2023.277801
Fathy, F., Thabet, R., Elgendy, A., abo el magd, N. Circulating IL 6 and IL 23 Levels in Systemic Lupus Erythematosus Patients and Association with Disease Activity. EKB Journal Management System, 2023; 32(1): 169-178. doi: 10.21608/ejmm.2023.277801

Circulating IL 6 and IL 23 Levels in Systemic Lupus Erythematosus Patients and Association with Disease Activity

Egyptian Journal of Medical Microbiology
Volume 32, Issue 1, January 2023, Page 169-178  XML PDF (603.58 K)
Document Type: New and original researches in the field of Microbiology.
DOI: 10.21608/ejmm.2023.277801
View on SCiNiTO View on SCiNiTO
Authors
Fatma el zahraa Y. Fathyorcid 1; Rasha N. Thabet2; Aya Elgendy3; Nagwa Mahmoud abo el magd email orcid 1
1Medical Microbiology and Immunology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
2Internal Medicine and Rheumatology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
3Internal Medicine and Allergy and Clinical Immunology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Abstract
Background: SLE is a systemic autoimmune disease that is characterized by immune mediated tissue damage. Objectives: to determine the serum levels of IL- 6 and IL-23 in SLE patients and to evaluate their association with disease parameters and activity. Methodology: The study included sixty participants that were divided into (30) SLE patients and (30) healthy controls (HCs). Lupus Erythematosus Disease Activity Index (SLEDAI-2K) was assessed. Serum IL-6 and IL-23 level were measured by ELISA in all participants. Results: The SLE patients were 28 females and 2 males with a mean age of 34±11 years. Thirty healthy controls were 27 females and 3 males with a mean age of 40±7 years. The mean disease duration was 6.31± 5.36 with the mean SLEDI-2K 9±7.24 patients had active disease, 73.3% had mucocutaneous manifestations as malar rash, alopecia and oral ulcers, 70% had arthritis, 10% had neuropsychiatric lupus and 17 cases had lupus nephritis confirmed by renal biopsy. IL-6 and IL-23 serum levels were significantly increased in SLE patients than the control group (p < 0.001). Serum IL-6 and IL-23 significantly discriminated SLE patients from healthy controls at a cut-off value of 112.5ng/L and 121.82 ng/L respectively with 83.3% and 96.7% sensitivity and 80% and 90% specificity respectively .Conclusion: Serum levels of IL-6 and IL-23 were elevated in SLE patients in comparison to control group and might be potential biomarkers for disease activity monitoring in SLE patients.
Keywords
Interleukin-6; Interleukin-23; SLE
Statistics
Article View: 192
PDF Download: 142